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MicroRNAs (miRNAs) are a class of endogenous, non-coding, 18–24 nucleotide length single-
strand RNAs that could modulate gene expression at post-transcriptional level. Previous studies
have shown that miR-128 enriched in the brain plays an important role in the development of
nervous system and the maintenance of normal physical functions. Aberrant expression of
miR-128 has been detected in many types of human tumors and its validated target genes are
involved in cancer-related biological processes such as cell proliferation, differentiation and apoptosis.
In this review, we will summarize the roles of miR-128 and its target genes in tumorigenesis and
metastasis.
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MicroRNAs (miRNAs) are a family of small non-coding single-
stranded RNAs. The primary function of miRNAs is to act as negative
regulators of gene expression at post-transcriptional level [1]. lin-4,
the ﬁrst discovered miRNA in 1993, regulated the development of
Caenorhabditis elegans via repressing expression level of lin-14
protein [2]. Another miRNA let-7 was demonstrated to mediate
the post-transcriptional regulation of its target gene expression [3].
It is known that miRNAs are identiﬁed virtually in all multicellular
organisms including plants, worms, arthropods, and vertebrates [4],
which can be either clustered or dispersed in the genome. To date,
there have been more than 4000 mature miRNAs found in humans,
which regulate about 30% of mammalian protein-coding genes. In
general, miRNAs suppress the mRNA translation or degrade the
target mRNAs through the interaction between 5′-“seed” region of
the miRNA and its perfectly complementary sequences located in
the 3′-UTRs of mRNAs[5–7]. Since Liu and coworkers ﬁrst reported
that the missing or ampliﬁed of miRNA expression in breast cancer
tissue frequently was correlated with the vulnerable regions in
human chromosome [8], accumulated evidence had showed that
miRNA genes were frequently located near genomic fragile as well
as in cancer-associated genomic regions [9]. Aberrant expression of
many miRNAs could be observed in most tumor types and some
were also related with the degree, stage, prognosis and therapeutic
response to malignant tumors [10,11]. It has been demonstrated that
miRNAs regulate the expression of their target genes related to
tumorigenesis and metastasis, including cell cycle regulation, differ-
entiation, apoptosis and invasion [12]. Some have oncogenic char-
acteristics and others appear as tumor-suppressor. Therefore,
miRNAs could also be divided into two groups: oncogenic and
tumor suppressor-like [13,14].
MicroRNA-128 (miR-128) is a brain-enriched miRNA. It has
been found that the expression of miR-128 has tissue-speciﬁc and
developmental-speciﬁc expression patterns, mainly in neurons
rather than in atrocities [15], and it is abundantly represented in
the hippocampal region of fetal, adult and Alzheimer's disease
brain [16]. It has been demonstrated that miR-128 plays an
important role in the development of nervous system and
maintenance of its normal physical functions [17]. The aberrant
expression of miR-128 could also be detected not only in tissues
but also in blood of some malignant tumor patients [18,19]. The
roles and mechanisms of miR-128 with its target genes in
tumorigenesis and metastasis will be reviewed as follows.miR-128 gene
Location and expression of miR-128 gene
miR-128 is a kind of intronic miRNAs and encoded by two distinct
genes, miR-128-1 and miR-128-2, which are embedded in theintrons of R3HDM1 (R3H domain containing 1) and RCS (ARPP-21,
cyclicAMP-regulated phosphoprotein, 21 kDa) genes located on
human chromosome 2q21.3 and 3p22.3 respectively [20]. Both
miR-128-1 and miR-128-2 are processed to generate the same
mature miRNAs with identical sequence, miR-128. It is also
known that majority of intronic miRNAs transcriptionally depend
on their host gene expression and processed from the same
primary transcript [21], which makes them to be conserved across
some species and mediates synergistic and antagonistic regula-
tory effects [22]. However, researchers also showed that about
26% of the mammalian intronic miRNAs might be transcribed
from their own promoters [23]. Monteys et al. demonstrated that
miR-128-2 had Pol III promoter in its 5′-ﬂanking region, which
might permit an independent expression of its host gene ARPP-21
[24]. Simultaneously Muinos-Gimeno et al. also found that there
were three SNPs located in the genomic region corresponding to
hsa-mir-128-1-R3HDM1, and there was a strong geographical
genetic variation among different populations from HapMap [25].
Expression of miR-128 in malignant tumors
Aberrant expression of miR-128 can be observed in many kinds of
malignant tumors. In hematopoietic malignant tumors, Zhu
measured the levels of miR-128 expression in the blood of 147
newly diagnosed acute leukemia patients and found that miR-128
was highly expressed in acute lymphoblastic leukemia (ALL)
patients, whereas there was no signiﬁcant difference between
acute myeloid leukemia (AML) patients and normal controls. They
speculated miR-128 was associated with the diagnosis and prog-
nosis of acute leukemia [26]. Fulci et al. reported that different
levels of miR-128 could be used to discriminate B-lineage ALL
subgroups harboring speciﬁc molecular lesions [27]. More strik-
ingly, the down-regulation of miR-128 in AML patients was
correlated with mutations in nucleophosmin (NPM1) [28]. Under-
expression of miR-128 was also observed in glioma as compared
to tumor-adjacent brain devoid of tumors or age-matched con-
trols, and particularly in more aggressive subtype such as
glioblastoma multiforme (GBM) and medulloblastoma based on
miRNA array, northern blot or qRT-PCR analyses [29–33]. Con-
versely, the expression level of miR-128 was obviously increased
in blood of glioblastoma patients [19]. However, the levels of
miR-128 expression in the other solid tumor tissues were
obviously different. Volinia and his colleagues measured 540
different kinds of malignant tumor samples and found that the
expression of miR-128b was signiﬁcantly up-regulated in tumor
tissues of colon, lung and pancreatic cancer through a large-scale
miRnome analysis [18]. In contrast, Katada and his colleagues
measured the expression levels of miR-128 in the specimens of 42
undifferentiated gastric cancer tissues and paired controls. Their
ﬁndings showed that mir-128a was up-regulated in undifferen-
tiated gastric cancer tissues while mir-128b was down-regulated
[34]. Khan et al. measured 21 independent prostate specimens
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and six metastatic prostate cancers) and the results displayed
a signiﬁcant reduction in the levels of miR-128 from benign
prostatic hyperplasia to prostate cancer to metastatic prostate
cancer in a progressive fashion [35]. Similar results could also be
detected in more invasive ovarian cancer cells than less invasive
ones [36]. Among 57 breast cancer patients by in situ hybridiza-
tion, Zhu et al. found that the expression of miR-128 was reduced
in the chemoresistant tumor tissues but increased in the chemo-
sensitive tissues. Furthermore they demonstrated that the level of
miR-128 expression in breast cancer tissues was correlated with
the response of breast tumor patients to novel adjuvant che-
motherapy and the survival of patients [37].
Mechanisms for miR-128 expression in tumor tissues
Based on miRNA processing, mature miRNAs are initially tran-
scripted by RNA polymerase II or III to form an endogenous
transcript (pri-miRNA); pri-miRNAs undergo processing by RNase
III enzyme Drosha and Dicer in the nucleus and change into
pre-miRNAs; pre-miRNAs are exported into the cytoplasm by
Ran-GTP dependent exportin-5, followed by further processing
[38]. Therefore, several factors could inﬂuence miR-128 expression.
Loss of heterozygosity (LOH) or ampliﬁcation located in miR-128
gene
LOH refers to the absence of functional gene in the lost region,
and ampliﬁcation refers to having an increased genomic copy
number. LOH or ampliﬁcation of total or part of chromosome
commonly occurred in cancer tissues, and both of them could
induce the alteration in the number of gene copies. It was
reported that LOH at chromosome 3p could be detected in 87%
of primary breast cancers [39]. Qian measured the expression of
miR-128-2 and its host gene ARPP21 mRNA by qPCR in 21 breast
cancer specimens and 15 benign breast disease tissues, and found
that the expression of ARPP21 mRNA was signiﬁcantly decreased
in breast cancer tissues compared with control specimens, and
similar expression pattern were observed in pri-miR-128-2 and
mature miR-128. They also demonstrated that miR-128-2 expres-
sion was signiﬁcantly in accordance with that of its host gene
ARPP21 [40]. LOH at chromosome 3p could also be detected in
96% of the lung cancers and 78% of preneoplastic/preinvasive
bronchial epithelium [41]. Moreover, miR-128 expression could
not be detected in non-small cell lung cancer cell lines and in
clinical non-small cell lung cancer tissues [42].
Point mutation or SNP existed in miR-128 gene
Kotani and his colleagues noticed that miR-128 gene, which was
cloned and sequenced from a cell line derived from an MLL-AF4
ALL patient, had a single nucleotide change A13G, located 13 bp
from the 3′ end of mature miR-128b. They further demonstrated
this mutation in miR-128 gene caused a signiﬁcant block in the
processing of miR-128b and a reduction in the level of the mature
miR-128b [43]. Besides this, Muinos-Gimeno et al. also showed
that R3HDM1 gene displays SNP among populations [25].Epigenetic alteration of miR-128 gene
DNA methylation in promoter regions may cause down-regulation
of the miRNA gene expression. In order to investigate thedifference of miR-128 expression between ALL and AML patients,
Mi et al. tested DNA methylation status of CpG-island located at
miR-128b promoters in 10 ALL, 14 AML, and three normal samples,
and they found that the average methylation rate of the ALL group
was 2.7%, lower than that of the AML group (17.1%). This result
suggests that up-regulation of miR-128b in ALL patients might
be due to low degree of CpG-island methylation in promoter
regions [44].
Regulated by transcriptional factors
It is known that SNAIL is a zinc ﬁnger transcriptional repressor,
which is usually expressed at high levels in tumors and exerts
oncogenic functions. It could down-regulate the expression of
miR-128 by directly binding to its promoter regions of both E-box
1 and 2 [40]. Forced expression of SNAIL reduced not only the
expression levels of mature miR-128 and pri-miR-128 but also the
expression of their host gene ARPP mRNA. Donzelli et al. noticed
that p53R175H, a hotspot p53 mutant, could induce miR-128-2
expression. They also found that mutant p53 protein, which is
characterized by increased stability and prolonged half-time
period, could bind to the putative promoter of miR128-2 host
gene ARPP21 and increase the expression of both miR-128 and
ARPP21 mRNA [45,46].
Changes of miRNA-associated genes and their proteins during
miRNA processing
It was reported that several miRNA-associated genes and their
proteins such as Drosha, DGCR8, Dicer etc could regulate miRNA
processing [38]. Therefore, it was speculated that the expression
of miR-128 might also be inﬂuenced.Roles of miR-128 in tumorigenesis and development
Numerous researches have demonstrated that miR-128 can
regulate proliferation, differentiation and apoptosis of various
tumor cells via targeting several genes such as Bmi-1 that are
mainly related with PI3K-AKT-mTOR signal pathway, indicating
miR-128 plays an important role in tumorigenesis and development
[47,48].
Inhibiting tumor proliferation
Transcription factor Bmi-1(B lymphoma mouse moloney leukemia
virus insertion region-1) is critical for the cell-cycle progression, and
it can act as a positive regulator for DNA damage response and
mitochondrial function [49]. It is also essential for promoting self-
renewal of several types of normal and cancer stem cells [50–53].
Up-regulation of Bmi-1 frequently occurs in many types of tumor
cells. It was demonstrated that Bmi-1 could regulate cell growth in
glioma cells by using transgenic mice [54]. Godlewski found that the
expression of miR-128 could be detected in brain, but not in glioma
cells, whereas the expression of Bmi-1 protein was up-regulated in
glioblastoma tissue, but not in normal brain. Overexpression of miR-
128 could signiﬁcantly reduce glioma cell proliferation in vitro and
glioma xenograft growth in vivo, accompanied by a decrease in
histone methylation (H3K27me(3)) and Akt phosphorylation, and
up-regulation of p21(CIP1) levels, consistent with Bmi-1 down-
regulation. Moreover, miR-128 was able to speciﬁcally block glioma
self-renewal by directly targeting Bmi-1[55]. Papagiannakopoulos
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capable of repressing growth and mediating differentiation of
glioma, while decreased miR-128 expression could be correlated
with aggressive human glioma subtypes. Furthermore they found
that miR-128 could repress glioma-initiating neural stem cells
(giNSC) self-renewal and enhance neuronal differentiation by target-
ing oncogenic receptor tyrosine kinases (RTKs), epithelial growth
factor receptor (EGFR) and platelet-derived growth factor receptor-α
(PDGFRα). Finally they demonstrated that miR-128 could repress
gliomagenesis by using an autochthonous glioma mouse model [56].
In another study, Venkataraman and his colleagues discovered that
miR-128a could increase intracellular ROS level by targeting Bmi-1
and inhibit medulloblastoma cell growth by promoting senescence
[57]. Palumbo demonstrated that Bmi-1 could affect aggrssive
growth-hormone(GH)-inducing pituitary tumor cell proliferation
by binding to PTEN promotor directly [58], thereby inbiting the
expression of PTEN, a negative regulator of the PI3K/AKT/mTOR
signaling pathway. In contrast, overexpression of miR-128 could
inhibit the proliferation of glioma cell through targeting p70S6K1, a
kind of serine/threonine kinase and one of the key downstream
targets of mammalian rapamycin (mTOR). Up-regulation of miR-128
could also suppress the expression of HIF-1 and VEGF, which were
p70S6K1 downstream molecules [59]. It was also reported that miR-
128 could also repress the proliferation of glioma cells by directly
targeting transcription factor E2F3 [60]. Besides, it is noticed that
miR-128a was up-regulated in the letrozole-resistant breast cancer
cells with loss of the sensitivity to transforming growth factor β
(TGFβ), whereas inhibition of endogenous miR-128a resulted in
re-sensitization of the letrozole-resistant cells to TGFβ growth
inhibitory effects. This result implies that miR-128a could directly
target transforming growth factor receptor I (TGFβRI) and play an
important role in regulating TGFβ signaling pathways and survival of
the letrozole-resistant cells involved in breast cancer progression
and aromatase inhibitors-resistance [61].Promoting tumor cell differentiation
It is known neurotrophins (NT) and their receptors are key factors
in regulating neuronal differentiation and survival, and they are
also related with the synaptic plasticity and neuronal cell survival
during development and mature. Neurotrophic tyrosine kinase
receptor type 3 (NTRK3) is a functional receptor for neurotrophin
3 (NT3), and it consists of two major isoforms: FL-NTRK3 (full-
length NTRK3) and TR-NTRK3 (truncated isoform of NTRK3). The
former has the activity of kinase while the latter is non-catalytic,
which has been veriﬁed to affect membrane remodeling, cytos-
keletal reorganization and cell movement [62,63]. Guidi studied
the role of miR-128 in the differentiation process of glioma by
using a glioblastoma cell model to ATRA. They found that over-
expression of miR-128 could induce glioblastoma cell differentia-
tion with rounded bodies and shorter neuritis etc morphology
changes, and increase the total number of differentiated cells.
The results indicated that ATRA promoted glioblastoma cell
differentiation accompanied by the up-regulation of miR-128 with
targeting TR-NTRK gene directly. When miR-128 was overexpressed,
the expression of several genes such as Bcl-2 was upregulated.
Therefore, miR-128 could function in the differentiation process of
glioblastoma associated with cell survival [64].Inﬂuencing apoptosis and drug resistance
Zhu and his colleagues noticed that miR-128 was signiﬁcantly
reduced in chemoresistant breast tumor initiating cells (BT-IC)
enriched by mammosphere cultures or CD44þCD24 ﬂuorescence-
activated cell sorting from breast cancer cell lines SK-3rd and MCF-7
and primary breast tumors, accompanied by an overexpression of
Bmi-1 and ABCC5(multidrug resistance-associated protein 5). Reduc-
tion in miR-128 might contribute to chemotherapeutic resistance
in breast cancer. They also found that ectopic expression of miR-128
could increase apoptosis and DNA damage via direct targeting
Bmi-1 and ABCC5 protein expression in BT-ICs when cooperating
with doxorubicin [37]. It is known that p53 mutations have
profound effects on non-small-cell lung cancer (NSCLC) resistance
to chemotherapeutic treatments, and mutant p53 proteins, usually
expressed at high levels in tumors, where they exert oncogenic
functions [46]. Donzelli observed that the increased expression of
miR-128-2 could inhibit lung cancer cells apoptosis and increases
resistance to cisplatin, doxorubicin and 5-ﬂuorouracyl treatments.
Further they demonstrated that miR-128-2 could target E2F5 at
post-transcriptional level and lead to the abrogation of its repressive
activity on p21 (waf1) transcription, where it exerted an anti-
apoptotic effect by preventing pro-caspase-3 cleavage. These results
suggest that miRNA-128-2 plays a master role in NSCLC chemore-
sistance [45].
Regulating EMT and inhibiting tumor cell invasion and
motility
Epithelial-to-mesenchymal transition (EMT) is a process in which
epithelial cells lose characteristic epithelial traits while gaining some
properties of mesenchymal cells. Recent studies have indicated that
EMT might play an important role in cancer invasion and metastasis
[65]. Qian and his colleagues demonstrated that overexpression of
miR-128 induced morphological transformation of MDA-MB-231
cells, from a spindle ﬁbroblast-like mesenchymal shape to a
cobblestone-like epithelial morphology, accompanied by decreasing
in both total cell number and colony formation number in soft agar,
as well as a retarded wound closing and a reduction in cell migration
and invasion compared with the control cells. This indicated that
miR-128 could inhibit the transformation of mammary epithelial
cells [40]. It is known that DCX is a microtubule-associated protein
and Reelin is an extracellular matrix glycoprotein secreted by Cajal-
Retzius cells, and both of them are involved in the migratory
potential of neuronal cells. By using cell model of neuroblastoma
cell differentiation, Evangelisti and his colleagues found that the
expression of miR-128 was greatly increased in SH-SY5Y cells after
ATRA treatment, while the repression of Reelin and DCX was
inhibited. They found that ectopic overexpression of miR-128 could
down-regulate glioblastoma cell invasion by directly targeting Reelin
and DCX [66]. By contrast, overexpression of miR-128 in ovarian
cancer cells resulted in reduction of cellular motility and adhesion
through direct targeting colony stimulating factor-1 (CSF-1) [36].Perspective
Aberrant expression of miR-128 in a broad type of tumor cells
indicates that miR-128 plays an important role in tumorigenesis and
E X P E R I M E N T A L C E L L R E S E A R C H 3 1 9 ( 2 0 1 3 ) 3 0 5 9 – 3 0 6 4 3063cancer development. This miRNA may be considered not only as a
key biomarker for diagnosis and prognosis of cancers, but also as an
effective agent for targeted therapy of malignant tumors. Under-
standing the mechanisms of miR-128 and its target genes under-
lying tumor proliferation, differentiation, apoptosis, invasion and
metastasis provides important cues to develop novel therapeutic
strategies for cancer prevention and treatment. Therefore, the
information generated from this review will explore the potential
of miR-128 as a promising therapeutic strategy for cancer therapy in
future.Conﬂict of interest
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